Agios Pharmaceuticals Inc (AGIO)
31.67
-0.14
(-0.44%)
USD |
NASDAQ |
Apr 24, 16:00
31.66
-0.01
(-0.03%)
Pre-Market: 20:00
Agios Pharmaceuticals Cash from Operations (Quarterly): -72.49M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -72.49M |
| September 30, 2023 | -61.64M |
| June 30, 2023 | -66.75M |
| March 31, 2023 | -95.18M |
| December 31, 2022 | -66.16M |
| September 30, 2022 | -71.35M |
| June 30, 2022 | -74.23M |
| March 31, 2022 | -97.74M |
| December 31, 2021 | -84.09M |
| September 30, 2021 | -85.18M |
| June 30, 2021 | -117.29M |
| March 31, 2021 | -120.75M |
| December 31, 2020 | -49.40M |
| September 30, 2020 | -68.21M |
| June 30, 2020 | -67.80M |
| March 31, 2020 | -105.36M |
| December 31, 2019 | -93.61M |
| September 30, 2019 | -85.59M |
| June 30, 2019 | -88.15M |
| March 31, 2019 | -103.27M |
| December 31, 2018 | -74.19M |
| September 30, 2018 | -63.84M |
| June 30, 2018 | -67.40M |
| March 31, 2018 | -99.00M |
| Date | Value |
|---|---|
| December 31, 2017 | -74.45M |
| September 30, 2017 | -77.72M |
| June 30, 2017 | -58.99M |
| March 31, 2017 | -74.07M |
| December 31, 2016 | -51.22M |
| September 30, 2016 | -49.03M |
| June 30, 2016 | 157.82M |
| March 31, 2016 | -19.01M |
| December 31, 2015 | -30.53M |
| September 30, 2015 | -24.82M |
| June 30, 2015 | 3.98M |
| March 31, 2015 | -25.58M |
| December 31, 2014 | -7.775M |
| September 30, 2014 | -23.47M |
| June 30, 2014 | -1.071M |
| March 31, 2014 | -27.04M |
| December 31, 2013 | -13.62M |
| September 30, 2013 | -14.98M |
| June 30, 2013 | -15.82M |
| March 31, 2013 | -11.98M |
| December 31, 2012 | -11.63M |
| September 30, 2012 | -11.40M |
| June 30, 2012 | -10.55M |
| March 31, 2012 | -15.97M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-120.75M
Minimum
Mar 2021
-49.40M
Maximum
Dec 2020
-82.68M
Average
-84.09M
Median
Dec 2021
Cash from Operations (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | -29.80M |
| Blueprint Medicines Corp | -78.93M |
| Corcept Therapeutics Inc | 5.887M |
| Ionis Pharmaceuticals Inc | 32.86M |
| Madrigal Pharmaceuticals Inc | -79.93M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 95.51M |
| Cash from Financing (Quarterly) | 0.847M |
| Free Cash Flow | -314.56M |
| Free Cash Flow Per Share (Quarterly) | -1.300 |
| Free Cash Flow to Equity (Quarterly) | -72.72M |
| Free Cash Flow Yield | -17.85% |